Molecular precision chemotherapy: overcoming resistance to targeted therapies?

Clin Cancer Res. 2014 Mar 1;20(5):1064-6. doi: 10.1158/1078-0432.CCR-13-3194. Epub 2014 Feb 17.

Abstract

Cytotoxic drugs may have specific effects on oncogenes and their downstream targets. Increase of cancer cell sensitivity due to repression of an oncogene downstream target can be specifically addressed by combined precision chemotherapy, increasing the therapeutic index of chemotherapy and overcoming resistance to highly selective targeted therapies.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Camptothecin / analogs & derivatives*
  • Camptothecin / pharmacology
  • DNA Damage / drug effects*
  • Dioxoles / pharmacology*
  • Female
  • Humans
  • Irinotecan
  • Oncogene Proteins, Fusion / antagonists & inhibitors*
  • Proto-Oncogene Protein c-fli-1 / antagonists & inhibitors*
  • RNA-Binding Protein EWS / antagonists & inhibitors*
  • Sarcoma, Ewing / genetics*
  • Sarcoma, Ewing / metabolism*
  • Tetrahydroisoquinolines / pharmacology*
  • Trabectedin

Substances

  • Antineoplastic Agents
  • Dioxoles
  • EWS-FLI fusion protein
  • Oncogene Proteins, Fusion
  • Proto-Oncogene Protein c-fli-1
  • RNA-Binding Protein EWS
  • Tetrahydroisoquinolines
  • Irinotecan
  • Trabectedin
  • Camptothecin